TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15853863
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR (days 1-3, 150 mg/day; days 4-49, 150 mg twice daily)
Study: 11292113
Drug: Inhaled Ems
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Ems salt
Study: 11292113
Drug: Inhaled isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled isotonic saline
Study: 11292113
Drug: Inhaled Ems
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Ems salt (cough group)
Study: 8619450
Drug: Two 400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 400-mg doses of artesunate followed by two doses of mefloquine (750 mg immediately and 500 mg 12 hr later)
Study: 8619450
Drug: Four 200-mg
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 200-mg doses of artesunate given 12 hr apart followed by a mefloquine regimen similar to Group I
Study: 8619450
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (four 200-mg doses of artesunate followed by mefloquine)
Study: 8619450
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (two 400-mg doses of artesunate followed by mefloquine)
Study: 3891239
Drug: Amcinonide ointment
Normalized name: Amcinonide Ointment
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide ointment applied twice daily for two weeks
Study: 3891239
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment applied twice daily for two weeks
Study: 30031995
Drug: Activity based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity based group therapy (1 hour duration, once a week for 4 weeks)
Study: 30031995
Drug: Activity based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity based group therapy
Study: 22743149
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day for 16 weeks
Study: 20483194
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia using liposomal lidocaine
Study: 20483194
Drug: Nurse-administered tactile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered tactile stimulation
Study: 10468689
Drug: EC‐ASA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐ASA 100 mg/day
Study: 10468689
Drug: Plain ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ASA 100 mg/day
Study: 1836097
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous nitroglycerin infusion
Study: 7201725
Drug: Tetravalent (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent (1, 3, 4, 12F) polysaccharide pneumococcal vaccine
Study: 7201725
Drug: Tetravalent (14,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent (14, 18C, 19F, 23F) vaccine
Study: 7201725
Drug: Pentadecavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentadecavalent vaccine (1, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14, 15F, 18C, 19F, 23F)
Study: 19581537
Drug: GEM (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM (standard treatment) 1,000 mg/m(2)/30 minutes
Study: 19581537
Drug: GEM FDR
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM FDR 1,500 mg/m(2)/150 minutes
Study: 19581537
Drug: GEMOX (GEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX (GEM 1,000 mg/m(2)/100 minutes + oxaliplatin 100 mg/m(2)/day 2 every 14 days)
Study: 20421430
Drug: 1.1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% amino acid solution
Study: 8739021
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily
Study: 9583841
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet (UD) with 1.2‐1.5 g protein/kg body wt
Study: 9583841
Drug: Chicken diet
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken diet (CD) with 1.2‐1.5 g protein/kg body wt
Study: 9583841
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) with 0.5‐0.8 g protein/kg body wt
Study: 7539186
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (holmium and diode lasers)
Study: 6732159
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment (34 patients)
Study: 29371061
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (monthly mailings and matched podcasts on non-weight related topics)
Study: 22412140
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (SLC) plus best supportive care (BSC)
Study: 22412140
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (SLC)
Study: 20151421
Drug: Sustained-release cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release cytarabine
Study: 20151421
Drug: Sustained-release cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release cytarabine (lumbar administration)
Study: 20151421
Drug: Sustained-release cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release cytarabine (ventricular administration)
Study: 20151421
Drug: Methotrexate (lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (lumbar administration)
Study: 20151421
Drug: Methotrexate (ventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (ventricular administration)
Study: 15677733
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure treatment after a minimum period of 8 weeks
Study: 12062776
Drug: Comprehensive Validation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Validation Therapy with 12-Step (CVT + 12S)
Study: 9416309
Drug: Glycerol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol administration
Study: 15990220
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 or 10 mg
Study: 15990220
Drug: Tolterodine extended
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended release (ER) 4 mg
Study: 12619955
Drug: Short acting
Normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short acting beta agonists as needed for mild episodic asthma
Study: 12619955
Drug: Bronchodilators with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators with daily maintenance treatment (low dose inhaled steroids, cromolyn, oral theophylline, leukotriene antagonists) for mild persistent asthma
Study: 12619955
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids with long acting beta agonists for moderate persistent asthma
Study: 12619955
Drug: Inhaled steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids, long acting beta agonists with or without theophylline for severe persistent asthma
Study: 12619955
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone on alternate days if symptoms are not well controlled
Study: 12619955
Drug: Cromolyn, short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn, short or long acting beta agonists, or leukotriene antagonists for exercise-induced bronchoconstriction
Study: 12619955
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment for children with seasonal asthma starting 2 weeks in advance and continued throughout the season
Study: 21722580
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation therapy
Study: 20735271
Drug: RTS,S/AS01(E) coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01(E) coadministered with EPI vaccines at 0, 1, and 2 months (3 doses)
Study: 20735271
Drug: RTS,S/AS01(E) coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01(E) coadministered with EPI vaccines at 0, 1, and 7 months (2 doses)
Study: 29213269
Drug: EPI vaccines
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI vaccines only
Study: 2312776
Drug: metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol CR/ZOK 50 mg
Study: 2878680
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg
Study: 2155948
Drug: metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol CR/ZOK 100 mg
Study: 27551051
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment
Study: 31479846
Drug: Yoga exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercise intervention (8 weeks, twice a week instructor-led and once a week home practice)
Study: 24237100
Drug: Chiropractic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic care including spinal manipulative therapy and massage
Study: 16148848
Drug: RIX4414 (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 (pooled vaccine groups)
Study: 16148848
Drug: RIX4414 (post-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 (post-dose 1 to 14 days post-dose 2)
Study: 11020919
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy with active participation of mothers
Study: 11020919
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy without active participation of mothers (control group)
Study: 8543554
Drug: Sertraline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (mean dose 87 mg/day)
Study: 8543554
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean dose 110 mg/day)
Study: 1805284
Drug: Aspartame chocolate
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame chocolate drink (80 mg)
Study: 1805284
Drug: Sucrose chocolate
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose chocolate drink (50 g)
Study: 23789288
Drug: Intravenous omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous omega-3 polyunsaturated fatty acids infusion
Study: 23789288
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution infusion (Control)
Study: 21368667
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (2 to 4 locally applied leeches)
Study: 21368667
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (30-day course)
Study: 17659263
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of sarcosine daily
Study: 17659263
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of sarcosine daily
Study: 17659263
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of sarcosine
Study: 10969521
Drug: i.v. tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tramadol (1 mg/kg)
Study: 8851611
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (500 mg)
Study: 8851611
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (125 mg and 250 mg)
Study: 6380356
Drug: Theophylline (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (therapeutic serum concentration averaged 13 mg/L, range 4.0 to 22.1)
Study: 1763589
Drug: Oxycodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (5 mg)
Study: 1632533
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 mg)
Study: 27401638
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering treatment (ezetimibe/simvastatin 10/40 mg, n=34)
Study: 27401638
Drug: Control statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control statin treatment (pravastatin 20 mg, n=36)
Study: 12700955
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 5 mg once daily
Study: 12700955
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 2.5 mg once daily
Study: 10355807
Drug: Sequential neuromotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential neuromotor examination at 3, 6, and 12 months
Study: 10355807
Drug: Sequential neuromotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential neuromotor examination at 12 months
Study: 10355807
Drug: Sequential neuromotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential neuromotor examination
Study: 10355807
Drug: Positive neonatal
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive neonatal urine drug screen for both cocaine and opiates
Study: 10355807
Drug: Positive maternal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive maternal drug screens for concurrent cocaine and opiate use
Study: 8918563
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (starting dose 100 mg/day for 20 weeks)
Study: 8918563
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (1 g/kg body weight for 2 consecutive days every 3 weeks, repeated six times)
Study: 29327055
Drug: Nab-paclitaxel, 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel, 125 mg/m2
Study: 29327055
Drug: Paclitaxel, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, 90 mg/m2
Study: 25265658
Drug: Standard cardioprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardioprotective therapy
Study: 2695862
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg/die/os for 12 weeks)
Study: 606771
Drug: Chemically disrupted
Normalized name: Membrane-disrupting peptide ep-100
DrugBank: Onvitrelin ucalontide (DB19183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically disrupted influenza A/New Jersey/76 virus vaccine
Study: 606771
Drug: Whole‐virus influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐virus influenza A/New Jersey/76 virus vaccine
Study: 606771
Drug: Preparation from
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation from Wyeth Laboratories
Study: 606771
Drug: Preparation from
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation from Parke, Davis and Company
Study: 606771
Drug: Preparation from
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation from Merrell‐National Laboratories
Study: 20127139
Drug: AZD6244 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 (100 mg twice daily)
Study: 20127139
Drug: Capecitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,250 mg/m2 twice daily for 2 weeks followed by 1-week rest)
Study: 19169187
Drug: Desvenlafaxine 200-400
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 200-400 mg/day
Study: 17113759
Drug: Amisulpride (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-600 mg/day)
Study: 17113759
Drug: Olanzapine (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-15 mg/day)
Study: 9389397
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further treatment after pancreaticoduodenectomy)
Study: 3360052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg i.v.
Study: 3360052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 400 mg p.o.
Study: 31969368
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 10 mg/kg plus pyridoxine for 12 months
Study: 16412796
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy (O-ET, 2 mg oral micronized 17beta estradiol daily)
Study: 16412796
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (T-ET, 17beta estradiol 1.5 mg gel daily)
Study: 15256300
Drug: Psycho-educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psycho-educational intervention (individual treatment session, two follow-up calls, information booklet)
Study: 11748518
Drug: Diltiazem (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (once-daily oral for at least 2 weeks)
Study: 3530302
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg triazolam
Study: 26268138
Drug: RP‐1127 (glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP‐1127 (glyburide for injection)
Study: 16200849
Drug: 0.05 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 U/kg insulin (group A)
Study: 16200849
Drug: 0.1 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 U/kg insulin (group B)
Study: 16200849
Drug: 0.05 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 U/kg insulin and 0.1 U/kg insulin
Study: 8737030
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (daytime glibenclamide and evening NPH insulin)
Study: 8737030
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (rapid acting insulin before meals and NPH insulin at bedtime)
Study: 3904543
Drug: IV aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV aminophylline loading dose
Study: 3904543
Drug: Oral aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aminophylline loading dose
Study: 16915380
Drug: Lorazepam (0.038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.038 mg/kg)
Study: 30770536
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy during rehabilitation
Study: 27682068
Drug: Oral Fusidic
Normalized name: fusidate
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fusidic Acid (FA) in combination with Oral Rifampin (RIF)
Study: 27682068
Drug: Standard-of-Care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-Care (SOC) intravenous antibiotics
Study: 24748637
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D2 50,000 IU monthly for 24 weeks (Ca+D)
Study: 24748637
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) alone (Ca)
Study: 18212316
Drug: Conventional diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diabetes therapy with a focus on weight loss by lifestyle change
Study: 16180593
Drug: Arm therapy
Normalized name: SOMBRA Warm Therapy 3 % / 3 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm therapy programme (15‐20 45‐min sessions) based on repetition of unilateral and symmetrical bilateral tasks
Study: 16180593
Drug: Usual arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual arm therapy of a similar duration and frequency to the experimental treatment
Study: 12966125
Drug: Shiga toxin-binding
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shiga toxin-binding agent (500 mg/kg daily for 7 days)
Study: 9001924
Drug: Tepoxalin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 25 mg
Study: 9001924
Drug: Tepoxalin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 100 mg
Study: 9001924
Drug: Tepoxalin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 200 mg
Study: 9001924
Drug: Tepoxalin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 400 mg
Study: 9001924
Drug: Tepoxalin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 800 mg
Study: 9001924
Drug: Tepoxalin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepoxalin 400 mg (multiple dose)
Study: 30869642
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - face-to-face CBT
Study: 27347792
Drug: Individual reminiscence
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual reminiscence sessions (5 weekly sessions)